化疗引起的疲劳不仅降低了患者的生活质量，也影响了患者的无复发生存率。尽管电针能够缓解疲劳，但对某些患者的疗效有限。因此，需要适当的生物标志物来帮助筛选哪些患者能从电针治疗疲劳中受益。我们进行了这项研究，以探讨单核苷酸多态性（SNPs）对乳腺癌患者辅助化疗后疲劳电针疗效的预测能力。我们的研究纳入了接受紫杉醇和/或蒽环类化疗后出现疲劳的乳腺癌患者。将患者分为电针组和对照组。电针治疗组接受了辅助化疗和电针治疗，而对照组仅接受了辅助化疗，然后比较了两组的疲劳缓解程度。此外，我们使用NCBI dbSNP和PharmGKB数据库选择了与疲劳相关的基因及其SNPs。我们收集了纳入患者的外周血进行SNPs分型，并记录了电针疗效，分析不同SNPs与治疗疗效之间的相关性。电针治疗的副作用也被记录下来。电针组纳入了76名患者，对照组纳入了48名患者。在电针组中，63名患者（82.9%）经历了中度至重度的疲劳（BFI评分>3）。经过电针治疗后，BFI评分>3的患者人数为46名（60.5%）。因此，有26.9%的患者的疲劳症状得到了显著改善（P<0.05）。在没有接受电针治疗的对照组中，48名患者中有40名BFI评分>3。在观察时间相同的情况下，36名患者BFI评分仍然>3。因此，对照组的疲劳症状没有得到显著缓解（83.3% vs. 75.0%，P>0.05）。我们在分析SNPs与电针治疗效果之间的相关性时纳入了56名患者。根据治疗效果，将患者分为治疗有效组和无效组。我们的结果表明，具有IL1A rs3783550 AC和CC基因型的电针治疗的有效率高于其他基因型（AC：84.6%，CC：81.8%，AA：33.0%，P<0.05）。同样地，具有HTR1A rs6295 GG和CC基因型的电针治疗的有效率高于其他基因型（GG：63.0%，CC：55.6%，GC：18.2%，P<0.05）。然而，没有其他基因型与电针治疗疲劳的效果相关。我们的结果显示，电针对乳腺癌辅助化疗后的疲劳具有治疗作用，并且其副作用是可以忍受的。此外，IL1A rs3763550和HTR1A rs6295可以预测电针治疗乳腺癌辅助化疗后的疲劳的治疗效果，从而有助于更好地筛选能够从电针治疗中受益的患者。(图10个) © 2023 作者，独家授权于Springer Science+Business Media, LLC，Springer Nature的一部分。

Chemotherapy-induced fatigue reduces not only the quality of life of patients but also effect their recurrence-free survival rate. Although electroacupuncture can relieve fatigue, it has limited affect on some patients. Therefore, appropriate biomarkers are needed to help screen patients who can benefit from electroacupuncture treatment of fatigue. We conducted this study to explore the predictive ability of SNPs on the efficacy of electroacupuncture in the treatment of fatigue in patients with breast cancer after adjuvant chemotherapy. Our study included breast cancer patients with fatigue after receiving paclitaxel and/or anthracycline based adjuvant chemotherapy. The patients were divided into the electroacupuncture group and the control group. The electroacupuncture treatment group received adjuvant chemotherapy and electroacupuncture treatment, while the control group only received adjuvant chemotherapy, and then compared the fatigue relief degree of two groups. In addition, we used NCBI dbSNP and PharmGKB databases to select fatigue related genes and their SNPs. We collected peripheral blood from the included patients for SNPs typing, and recorded the efficacy of electroacupuncture to analyzed the correlation between different SNPs and therapeutic efficacy. The side effects of electroacupuncture treatment were also recorded. 76 patients in the electroacupuncture group and 48 patients in the control group were enrolled. In the electroacupuncture group, 63 patients (82.9%) experienced moderate to severe fatigue (BFI score > 3). After electroacupuncture treatment, the number of patients with a BFI score of > 3 was 46 (60.5%). Therefore, the fatigue symptoms of 26.9% patients were significantly improved (P < 0.05). In the control group, which did not receive electroacupuncture treatment, 40 of 48 patients had a BFI score of > 3. Following the same observation time used in the electroacupuncture group, 36 patients had a BFI score of > 3 points. Thus, fatigue was not significantly relieved in the control group (83.3% vs. 75.0%, P > 0.05). We included 56 patients in our analysis of the correlation between SNPs and electroacupuncture treatment effects. We divided the patients into an effective group and ineffective group according to therapeutic effects. Our results indicated that the effective rate of electroacupuncture treatment with IL1A rs3783550 AC and CC genotypes was higher than that with other genotypes (AC: 84.6%, CC: 81.8%, AA: 33.0%, P < 0.05). Similarly, the effective rate of electroacupuncture treatment with HTR1A rs6295 GG and CC genotypes was higher than that with other genotypes (GG: 63.0%, CC: 55.6%, GC: 18.2%, P < 0.05). However, no other genotypes were related to the effect of electroacupuncture treatment on fatigue. Our result showed that electroacupuncture has therapeutic effect on fatigue after adjuvant chemotherapy for breast cancer and the side effects are tolerable. In addition, IL1A rs3763550 and HTR1A rss6295 can predict the therapeutic effect of electroacupuncture on fatigue after adjuvant chemotherapy in breast cancer, which helps to better screen patients who can benefit from electroacupuncture treatment.© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.